Sodium-glucose co-transporter 2 inhibitors and hematopoiesis

Habib Yaribeygi, Mina Maleki, Fatemeh Nasimi, Alexandra E. Butler, Tannaz Jamialahmadi, Amirhossein Sahebkar

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)


Many patients with diabetes mellitus, especially those with chronic kidney disorders, have some degree of anemia due to a spectrum of causes and underlying pathophysiologic pathways. As such, enhancement in erythropoiesis is important in these patients. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a relatively new class of antidiabetic drugs with confirmed protective effects in kidney and cardiovascular tissues. Recent evidence suggests that these drugs may provide additional benefits in enhancing hematopoietic processes in diabetic patients. Though the exact mediating pathways have not been fully elucidated, cellular mechanisms are likely involved. In the current study, we present the potential pathways by which SGLT2i may modulate hematopoiesis and stimulate erythropoiesis.
Original languageEnglish
Pages (from-to)3778-3787
Number of pages10
JournalJournal of Cellular Physiology
Issue number10
Early online date11 Aug 2022
Publication statusPublished - Oct 2022


Dive into the research topics of 'Sodium-glucose co-transporter 2 inhibitors and hematopoiesis'. Together they form a unique fingerprint.

Cite this